These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 37326480)
1. Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARS-CoV-2 in Adult Patients with Immune-Mediated Inflammatory Diseases. Cheung MW; Dayam RM; Shapiro JR; Law JC; Chao GYC; Pereira D; Goetgebuer RL; Croitoru D; Stempak JM; Acheampong L; Rizwan S; Lee JD; Jacob L; Ganatra D; Law R; Rodriguez-Castellanos VE; Kern-Smith M; Delgado-Brand M; Mailhot G; Haroon N; Inman RD; Piguet V; Chandran V; Silverberg MS; Watts TH; Gingras AC J Immunol; 2023 Aug; 211(3):351-364. PubMed ID: 37326480 [TBL] [Abstract][Full Text] [Related]
2. Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases. Dayam RM; Law JC; Goetgebuer RL; Chao GY; Abe KT; Sutton M; Finkelstein N; Stempak JM; Pereira D; Croitoru D; Acheampong L; Rizwan S; Rymaszewski K; Milgrom R; Ganatra D; Batista NV; Girard M; Lau I; Law R; Cheung MW; Rathod B; Kitaygorodsky J; Samson R; Hu Q; Hardy WR; Haroon N; Inman RD; Piguet V; Chandran V; Silverberg MS; Gingras AC; Watts TH JCI Insight; 2022 Jun; 7(11):. PubMed ID: 35471956 [TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 live virus neutralization after four COVID-19 vaccine doses in people with HIV receiving suppressive antiretroviral therapy. Cheung PK; Lapointe HR; Sang Y; Ennis S; Mwimanzi F; Speckmaier S; Barad E; Dong W; Liang R; Simons J; Lowe CF; Romney MG; Brumme CJ; Niikura M; Brockman MA; Brumme ZL; AIDS; 2023 Apr; 37(5):F11-F18. PubMed ID: 36789806 [TBL] [Abstract][Full Text] [Related]
4. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants. Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765 [TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of mixed COVID-19 vaccine regimens in patients with immune-mediated inflammatory diseases: a single-centre prospective cohort study. Hitchon CA; Mesa C; Bernstein CN; Marrie RA; Card C; O'Brien SF; Kim J BMJ Open; 2023 May; 13(5):e071397. PubMed ID: 37253487 [TBL] [Abstract][Full Text] [Related]
6. Longitudinal cellular and humoral immune responses after triple BNT162b2 and fourth full-dose mRNA-1273 vaccination in haemodialysis patients. Becker M; Cossmann A; Lürken K; Junker D; Gruber J; Juengling J; Ramos GM; Beigel A; Wrenger E; Lonnemann G; Stankov MV; Dopfer-Jablonka A; Kaiser PD; Traenkle B; Rothbauer U; Krause G; Schneiderhan-Marra N; Strengert M; Dulovic A; Behrens GMN Front Immunol; 2022; 13():1004045. PubMed ID: 36275672 [TBL] [Abstract][Full Text] [Related]
7. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study. Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735 [TBL] [Abstract][Full Text] [Related]
8. Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial. Thakkar A; Pradhan K; Duva B; Carreno JM; Sahu S; Thiruthuvanathan V; Campbell S; Gallego S; Bhagat TD; Rivera J; Choudhary G; Olea R; Sabalza M; Shapiro LC; Lee M; Quinn R; Mantzaris I; Chu E; Will B; Pirofski LA; Krammer F; Verma A; Halmos B Elife; 2023 Mar; 12():. PubMed ID: 36975207 [TBL] [Abstract][Full Text] [Related]
9. Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic. Kennedy NA; Janjua M; Chanchlani N; Lin S; Bewshea C; Nice R; McDonald TJ; Auckland C; Harries LW; Davies M; Michell S; Kok KB; Lamb CA; Smith PJ; Hart AL; Pollok RC; Lees CW; Boyton RJ; Altmann DM; Sebastian S; Powell N; Goodhand JR; Ahmad T Gut; 2023 Feb; 72(2):295-305. PubMed ID: 35902214 [TBL] [Abstract][Full Text] [Related]
10. Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2. Woelfel S; Dütschler J; König M; Graf N; Oikonomou V; Krieger C; Truniger S; Franke A; Eckhold A; Forsch K; Wyss J; Krupka N; Albrich W; Frei N; Geissler N; Schaub P; ; Friedrich M; Misselwitz B; Korte W; Bürgi JJ; Brand S Aliment Pharmacol Ther; 2023 Jan; 57(1):103-116. PubMed ID: 36307899 [TBL] [Abstract][Full Text] [Related]
11. The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study. Christensen IE; Jyssum I; Tveter AT; Sexton J; Tran TT; Mjaaland S; Kro GB; Kvien TK; Warren DJ; Jahnsen J; Munthe LA; Haavardsholm EA; Vaage JT; Grødeland G; Lund-Johansen F; Jørgensen KK; Syversen SW; Goll GL; Provan SA BMC Med; 2022 Oct; 20(1):378. PubMed ID: 36199139 [TBL] [Abstract][Full Text] [Related]
12. Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients receiving secukinumab: a literature review. Gisondi P; Simon D; Alarcon I; Pournara E; Puig L J Dermatolog Treat; 2023 Dec; 34(1):2167487. PubMed ID: 36625506 [No Abstract] [Full Text] [Related]
13. SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease. Wagner A; Garner-Spitzer E; Schötta AM; Orola M; Wessely A; Zwazl I; Ohradanova-Repic A; Weseslindtner L; Tajti G; Gebetsberger L; Kratzer B; Tomosel E; Kutschera M; Tobudic S; Pickl WF; Kundi M; Stockinger H; Novacek G; Reinisch W; Zielinski C; Wiedermann U Front Immunol; 2022; 13():889138. PubMed ID: 35634285 [TBL] [Abstract][Full Text] [Related]
14. Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters. Rescigno M; Agrati C; Salvarani C; Giannarelli D; Costantini M; Mantovani A; Massafra R; Zinzani PL; Morrone A; Notari S; Matusali G; Pinter GL; Uccelli A; Ciliberto G; Baldanti F; Locatelli F; Silvestris N; Sinno V; Turola E; Lupo-Stanghellini MT; Apolone G; Front Immunol; 2023; 14():1104124. PubMed ID: 36776853 [TBL] [Abstract][Full Text] [Related]
15. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis. Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D Front Immunol; 2022; 13():846753. PubMed ID: 35309297 [TBL] [Abstract][Full Text] [Related]
17. The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and quality under TNFα blockade. Geisen UM; Rose R; Neumann F; Ciripoi M; Vullriede L; Reid HM; Berner DK; Bertoglio F; Hoff P; Hust M; Longardt AC; Lorentz T; Martini GR; Saggau C; Schirmer JH; Schubert M; Sümbül M; Tran F; Voß M; Zeuner R; Morrison PJ; Bacher P; Fickenscher H; Gerdes S; Peipp M; Schreiber S; Krumbholz A; Hoyer BF J Med Virol; 2022 Dec; 94(12):5780-5789. PubMed ID: 35945627 [TBL] [Abstract][Full Text] [Related]
18. T-Cell Mediated Response after Primary and Booster SARS-CoV-2 Messenger RNA Vaccination in Nursing Home Residents. Schiavoni I; Palmieri A; Olivetta E; Leone P; Di Lonardo A; Mazzoli A; Cafariello C; Malara A; Palamara AT; Incalzi RA; Onder G; Stefanelli P; Fedele G; J Am Med Dir Assoc; 2023 Feb; 24(2):140-147.e2. PubMed ID: 36587928 [TBL] [Abstract][Full Text] [Related]
19. mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in naïve and COVID-19-recovered individuals. Lozano-Rodríguez R; Avendaño-Ortíz J; Terrón V; Montalbán-Hernández K; Casalvilla-Dueñas J; Bergón-Gutiérrez M; Mata-Martínez P; Martín-Quirós A; García-Garrido MÁ; Del Balzo-Castillo Á; Peinado M; Gómez L; Llorente-Fernández I; Martín-Miguel G; Herrero-Benito C; López-Morejón L; Vela-Olmo C; Cubillos-Zapata C; López-Collazo E; Del Fresno C Front Immunol; 2023; 14():1136029. PubMed ID: 37153580 [TBL] [Abstract][Full Text] [Related]
20. Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines. Isnardi CA; Cerda OL; Landi M; Cruces L; Schneeberger EE; Montoro CC; Alfaro MA; Roldán BM; Gómez Vara AB; Giorgis P; Ezquer RA; Crespo Rocha MG; Reyes Gómez CR; de Los Ángeles Correa M; Rosemffet MG; Abarza VC; Pellet SC; Perandones M; Reimundes C; Longueira Y; Turk G; Quiroga MF; Laufer N; Quintana R; de la Vega MC; Kreplak N; Pifano M; Maid P; Pons-Estel GJ; Citera G J Rheumatol; 2022 Dec; 49(12):1385-1389. PubMed ID: 36182107 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]